---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-010427"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2024-04-01T23:59:59+00:00"
generated_at: "2026-06-04T04:25:48.254728+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vistagen enrolls first patient in PALISADE-3 Phase 3 fasedienol trial for social anxiety disorder

## Summary
- PALISADE-3 is a randomized, double-blind, placebo-controlled study of ~236 adults aged 18–65 with SAD.
- Primary endpoint is patient-rated SUDS; patients randomized 1:1 to fasedienol or placebo.
- Follows positive PALISADE-2 results; PALISADE-4 replication planned for H2 2024.
- Social anxiety disorder affects over 25 million Americans; fasedienol is an investigational pherine.
- CEO Shawn Singh calls the initiation a 'major milestone' toward first-in-class treatment.

## SEC filing metadata
- accession: 0001437749-24-010427
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2024-04-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000143774924010427/0001437749-24-010427-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000143774924010427/vtgn20240401_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-010427
- JSON: https://secwatch.observer/filing/0001437749-24-010427.json
- Plain text: https://secwatch.observer/filing/0001437749-24-010427.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.